Health & Healthcare

IAIC Launches First Multi-Region Study on Ageing and Ageing Well, Advancing Global Collaboration and Research in Integrated Care

SINGAPORE – Media OutReach Newswire – 21 November 2025 – The Intercontinental Alliance for Integrated Care (IAIC), hosted by the Singapore University of Social Sciences (SUSS), today launched its first-ever multi-region study on the perceptions of ageing and ageing well. Now in its second edition, the Alliance’s annual flagship event IAIC 2025 brought together partners from across […]

IAIC Launches First Multi-Region Study on Ageing and Ageing Well, Advancing Global Collaboration and Research in Integrated Care Read More »

NUH Unveils New One-Stop Orthopaedic Surgery and Hand & Reconstructive Microsurgery Centres

Integrated hub redefines patient care, sustainability and future-ready design SINGAPORE – Media OutReach Newswire – 17 November 2025 – The National University Hospital (NUH) has launched the new Orthopaedic Surgery and Hand & Reconstructive Microsurgery Centres, integrating key specialist services – from consultations and surgery to diagnostics, physical therapy and pharmacy stops – into one

NUH Unveils New One-Stop Orthopaedic Surgery and Hand & Reconstructive Microsurgery Centres Read More »

Ascott Launches Holistic Disability Inclusion Playbook for Accommodation Sector, Setting New Hospitality Benchmark

SINGAPORE – Media OutReach Newswire – 17 November 2025 – The Ascott Limited (Ascott), the wholly owned lodging business unit of CapitaLand Investment (CLI), has launched the Disability Inclusion Playbook for the Accommodation Sector. As one of the world’s first open-access, holistic disability inclusion playbooks, it sets a new benchmark for inclusive hospitality. Developed by Ascott in

Ascott Launches Holistic Disability Inclusion Playbook for Accommodation Sector, Setting New Hospitality Benchmark Read More »

Positioning Barbados as the Caribbean’s Life Sciences Hub

EarlyHealth City to Anchor US$200 Million Investment

BRIDGETOWN, Barbados, Nov. 14, 2025 (GLOBE NEWSWIRE) — Export Barbados (BIDC) and EarlyHealth Group (EHG), headquartered in Dubai, United Arab Emirates, have signed a Letter of Intent to jointly establish EarlyHealth City Barbados, a US$200 Million world-class pharmaceutical and life sciences cluster earmarked for Newton, Christ Church. The initiative is expected to attract international pharmaceutical partners, drive industrialisation through sustainable contract manufacturing, and expand laboratory and clinical research capacity in Barbados and for the wider Caribbean.

Located across 45 acres, EarlyHealth City will feature three domes totaling more than 250,000 square feet of contract manufacturing space dedicated to the production of oral solids, semi-solids, liquids, and advanced biologics. This includes integrated capabilities for cell cultivation, upstream and downstream bioprocessing, and full scale-up to commercial release under United States and European Union Good Manufacturing Practice (GMP) standards.

EHG, a global pharmaceutical services and life sciences company supporting manufacturing, clinical studies, and market access across 60 countries, has already secured Memorandum of Understandings (MOUs) with a number of clients including Acarpia Farmaceutici Srl, Bioeq AG, Formycon AG, Swedish Orphan Biovitrum (SOBI), and several Asian-, European-, and South American-based manufacturers.

The City will incorporate a fourth dome housing a Security Operations Centre (SOC), designed and managed by EHG’s business partner and Dubai’s fastest-growing cybersecurity and data protection company Cyb3r Limited. The SOC is expected to feature an AI-driven cybersecurity and data-analytics infrastructure intended to safeguard digital assets, manage regulatory data, and provide secure network operations for the life sciences cluster. The same dome will also house a 30,000 square foot high-performance cricket training facility operated by global sports company DriveFITT. That facility is expected to integrate cutting-edge biomechanics and recovery technology to enhance athletic performance and to train and nurture new generations of West Indies fast bowlers.

EarlyHealth City

Prime Minister the Hon Mia Amor Mottley, SC, MP, noted that Barbados is committed to providing the infrastructure, investment, and oversight required to deliver what she called a “transformative project” for the island. She explained that “beyond infrastructure, EarlyHealth City Barbados will drive job creation and build local scientific and technical talent, allowing Barbadians to play a central role in developing a new industry. It is a cornerstone of Barbados’ economic future, embedding pharmaceutical innovation and production directly into our industrial base.”

Dr. Dan A. Renout, Chief Executive Officer of EarlyHealth Group, the driving force behind the initiative, observed that “EarlyHealth City Barbados is more than a manufacturing site. It is a platform for transformation. By combining world-class standards and building local talent and innovation, we are creating an ecosystem that strengthens supply resilience, generates skilled employment, and connects the Caribbean to the global pharmaceutical industry.”

EarlyHealth City

Once complete, EarlyHealth City Barbados will host a community of more than 1,000 professionals, offering wellness amenities, restaurants, and collaborative workspaces that reflect a modern, sustainable lifestyle. Together, these facilities will form the Caribbean’s premier life sciences hub.

Senior Minister Coordinating the Productive Sector and Minister of Foreign Affairs and Foreign Trade the Hon. Kerrie Symmonds hailed EarlyHealth City Barbados as a leading example of commercial diplomacy at its finest. He noted the critical role the Embassy of Barbados in the UAE and its Ambassador Her Excellency Dr. Annalee C. Babb are playing in helping EHG develop a number of critical value propositions for the island, culminating in the proposed life sciences city.

Minister of Innovation, Industry, Science and Technology Senator the Hon. Jonathan Reid observed that “Barbados is taking decisive steps to join the ranks of countries leading in life sciences and pharmaceutical innovation, building a foundation for sustainable economic growth and global competitiveness.” The Minister lauded Export Barbados, its Chairman Mr. Dodridge Miller, and its Chief Executive Officer Mr. Mark Hill for their ingenuity and foresight in not only leading the conceptualisation of Barbados as a regional hub for the global life sciences sector, but also in designing an iconic building he believes can serve as a prototype for new approaches to high-end pharmaceutical manufacturing.

EarlyHealth City

About EarlyHealth Group
EarlyHealth Group (EHG) is a global pharmaceutical services and life sciences company supporting manufacturing, clinical studies, and market access across 60 countries. The Group partners with manufacturers, research institutions, and governments to make healthcare accessible through compliant, end-to-end solutions across the value chain.

About Export Barbados
Export Barbados (BIDC) is the state-owned enterprise that drives Barbados’ industrialisation and export growth. The agency develops infrastructure, supports innovation, and partners with global companies to strengthen Barbados’ position as a competitive exporter of goods and services, with a focus on life sciences, manufacturing, and sustainable industries.

Photos accompanying this announcement are available at:

https://www.globenewswire.com/NewsRoom/AttachmentNg/219aaac2-0f40-45aa-9e7f-48e56b8b2cf1

https://www.globenewswire.com/NewsRoom/AttachmentNg/53be00d8-50b2-4cbf-91dc-9b1b65b4046c

https://www.globenewswire.com/NewsRoom/AttachmentNg/036fb1db-d93f-4bde-ad18-2fdc99d5d027

CONTACT: Media Contact
EarlyHealth City Communications
Email: communications@early-health.city

Positioning Barbados as the Caribbean’s Life Sciences Hub Read More »

Flu Wave Hits Southeast Asia, Highlighting Gaps in Protection for the Elderly

HO CHI MINH CITY, VIETNAM – Media OutReach Newswire – 5 November 2025 – Many countries in Asia are reporting a sharp rise in flu cases. The intensified rainy season is fueling transmission and creating ideal conditions for rapid spread. In a single week, Thailand recorded more than 30,000 new cases.1 Meanwhile, Japan declared a nationwide flu epidemic

Flu Wave Hits Southeast Asia, Highlighting Gaps in Protection for the Elderly Read More »

ICP DAS-BMP Redefines Medical Material Performance with Low-Migration and Low-Friction TPU at COMPAMED 2025 

HSINCHU, Nov. 4, 2025 /PRNewswire/ — ICP DAS-BMP (Biomedical Polymers), a Taiwan-based manufacturer and supplier of medical-grade TPU (thermoplastic polyurethane), is pleased to announce its participation in COMPAMED 2025, taking place from November 17 to 20 at Messe Düsseldorf, Germany. Visitors can find the ICP DAS-BMP team at Hall 8b, Booth C09-4. The highlight of this year’s exhibit will be two TPU innovations designed

ICP DAS-BMP Redefines Medical Material Performance with Low-Migration and Low-Friction TPU at COMPAMED 2025  Read More »

Avance Clinical Showcases Early Phase Expertise and the Australian Advantage for EU Biotechs at BIO-Europe Vienna

Helping European Biotechs Accelerate Early Phase Success With Faster Timelines, Lower Costs, and Globally Accepted Data

ADELAIDE, Australia, Nov. 03, 2025 (GLOBE NEWSWIRE) — Avance Clinical, the largest premium full-service Australian headquartered CRO with more than 30 years of early phase expertise, is highlighting its Early Phase Center of Excellence for Biotechs and the well-established Australian Advantage to European biotechs ahead of BIO-Europe in Vienna, November 3-5, 2025.

Avance Clinical Showcases Early Phase Expertise and the Australian Advantage for EU Biotechs at BIO-Europe Vienna

European biotechs under increasing investor and regulatory pressure are turning to Avance Clinical’s proven Australian pathway to achieve first-in-human (FIH) and early proof-of-concept studies with:

  • Startup timelines in as little as 5-6 weeks from final protocol to study approval through Australia’s streamlined regulatory frameworks (CTN/CTA) and Avance Clinical’s deep early phase expertise
  • Globally accepted trial data, recognized by EMA, FDA, and other regulators
  • Up to 43.5% cash rebate through Australia’s R&D tax incentive program
  • Seamless progression to global trials through Avance Clinical’s GlobalReady program and worldwide partner network of 2,000+ sites

“EU biotechs are often surprised to learn just how efficient Australia is for early phase research,” said Mark Harvill, CEO of Avance Clinical. “Our new Early Phase Center of Excellence for Biotechs underscores our commitment to scientific rigor, innovation, and helping sponsors reach critical milestones faster — without compromising quality.”

Avance Clinical has guided more than 710 emerging biotechs across 250+ therapeutic indications, supported by in-house scientific and regulatory affairs expertise, and best-in-class clinical operations. Its dedicated Early Phase Center of Excellence for Biotechs was designed specifically to meet the needs of international biotech sponsors navigating complex first-in-human and early development studies.

“With growing competition in biotech, speed and quality in early development are critical,” said Ben Edwards, Chief Operating Officer of Avance Clinical. “By combining the Australian Advantage, which offers up to 43.5% Australian Government R&D tax rebate, with our deep early phase expertise, EU sponsors can de-risk their programs and maintain capital efficiency while advancing quickly to global markets.”

Meet Avance Clinical at BIO-Europe Vienna

European biotechs attending BIO-Europe 2025 are invited to meet with Liahna Toy, Vice President, Commercial Business Development, and Dewald Jacobs, Director of Business Development, at Booth #C185 at the Vienna Congress & Convention Center (Messe Wien), November 3-5, 2025.

This is a unique opportunity for EU sponsors to discuss how Avance Clinical’s early phase expertise and the Australian Advantage can accelerate development pipelines.

Book a Meeting Now

About Avance Clinical

Avance Clinical is the largest premium full-service Australian headquartered CRO delivering high-quality clinical trials in Australia, New Zealand, Asia, North America, and Europe for international biotechs. The company has won multiple Frost & Sullivan CRO Market Leadership and Customer Value Leadership Awards.

With over 30 years of experience and cross-therapeutic expertise in more than 250 indications, Avance Clinical provides services from pre-clinical to late-phase trials, supported by best-in-class regulatory, clinical, and operational teams.

Find out more:

CONTACT:
Gabe Martinez
Director Content, Media, & PR
308-237-5567
Pr@scorrmarketing.com

A photo accompanying this announcement is available at: https://www.globenewswire.com/NewsRoom/AttachmentNg/6bdfcdd6-822b-4af9-aa9a-832fc449ca24

Avance Clinical Showcases Early Phase Expertise and the Australian Advantage for EU Biotechs at BIO-Europe Vienna Read More »

Allianz Partners urges travellers to rethink coverage as new data shows Aussies still travelling uninsured

BRISBANE, Australia, Oct. 22, 2025 /PRNewswire/ — Allianz Partners is urging Australian travellers to rethink their approach to travel insurance, following new ICA and DFAT research revealing that one in seven travellers are still going overseas uninsured. The findings underscore Allianz Partners’ ongoing commitment to helping Australians when things go wrong overseas. “It is concerning that those

Allianz Partners urges travellers to rethink coverage as new data shows Aussies still travelling uninsured Read More »

Senna Wellness Retreat brings Mid-Autumn festival to 700 children in Sin Suoi Ho Commune, Lai Chau Province through the ‘Trăng Lên Đỉnh Núi’ campaign

BAC NINH, Vietnam, Oct. 22, 2025 /PRNewswire/ — Senna Wellness Retreat has successfully completed ‘Trăng Lên Đỉnh Núi’ (Moonrise over the mountain) campaign with a charitable trip to Sin Suoi Ho Commune, Lai Chau Province on October 02, 2025. The visit marked the completion of a two-month journey dedicated to bringing a meaningful Mid-Autumn Festival to children and local residents

Senna Wellness Retreat brings Mid-Autumn festival to 700 children in Sin Suoi Ho Commune, Lai Chau Province through the ‘Trăng Lên Đỉnh Núi’ campaign Read More »

JOY GROUP Completes Acquisition of Italian Dermatological Hair Care Brand Foltène

SHANGHAI, Oct. 21, 2025 /PRNewswire/ — China’s leading multi-brand beauty group JOY GROUP (Shanghai Juyi Cosmetics Co., Ltd.) has announced the completion of its acquisition of Foltène, a dermatological hair care brand from Italy. Founded in Milan in 1944 by pharmaceutical researchers, Foltène is renowned for its scientific heritage and pioneering innovation. The brand developed two proprietary active complexes, Tricosaccaride® and Tricalgoxyl®,

JOY GROUP Completes Acquisition of Italian Dermatological Hair Care Brand Foltène Read More »